Full Press Release Details
van Dyck, C.H., Mecca, A.P., O’Dell, R.S. et al. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease . Alz Res Therapy 16, 20 (2024).
CGTX Positive Sentiment
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
Key Takeaway: A pilot study led by van Dyck et al. investigates the impact of CT1812 on synaptic density and other biomarkers in Alzheimer's disease. The research aims to assess the treatment's efficacy in enhancing cognitive functions. Results from this study could provide valuable insights into new therapeutic approaches for Alzheimer's.
Price reaction · baseline $2.43 (2024-01-24 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
-6.6%
day 1
-1.2%
day 3
-3.3%
Market Sentiment Analysis
POSITIVE FACTORS
- CT1812 shows potential in improving synaptic density.
- The study addresses critical biomarkers in Alzheimer's disease.
- Pilot study indicates promising results for Alzheimer's treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Frequently Asked Questions
What is the focus of the CT1812 pilot study?
The study focuses on evaluating CT1812's effect on synaptic density and biomarkers in Alzheimer's disease.
Who conducted the CT1812 pilot study?
The pilot study was conducted by van Dyck, C.H., Mecca, A.P., O'Dell, R.S., and others.
What are the potential benefits of CT1812?
CT1812 may improve synaptic density and cognitive functions in Alzheimer's patients.
Where was the study on CT1812 published?
The study was published in Alz Res Therapy.